Skip to content

Price / sales at other companies

United Therapeutics logo
United TherapeuticsUTHR
8.2×+3.6×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
9.8×+4.0×
Arrowhead Research logo
Arrowhead ResearchARWR
14.1×+10.9×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
11.7×+5.0×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
24.8×-26.8×
TG Therapeutics logo
TG TherapeuticsTGTX
7.6×-8.5×

Other financials

Income statement

See full
Revenue$132.9M+4,158%
Gross profit$1.6M+6.5%
Operating income$61.5M+274%
Net income$52.9M+238%
EPS (diluted)$0.52+216%

Balance sheet

See full
Cash & equivalents$222.8M+31.2%
Total debt$7.0M+1.5%
Total equity$108.6M+118%
Total assets$401.5M+76.6%

Cash flow

See full
Operating cash flow$53.0M+273%
CapEx$2.8M+758%
Free cash flow$50.2M+262%

Valuation

See full
Market cap$6.32B+164%
Enterprise value$6.1B+184%

Profitability

See full
Gross margin58.1%-18.7pp
Operating margin-155%-68.1pp
Net margin-176.2%-76.4pp
FCF margin-150.7%-64.4pp

Returns & leverage

See full
Return on equity-181%+57.4pp
Debt / equity0.1×-0.1×
Current ratio2.2×-0.7×

Where this comes from

Calculated from Liquidia Corporation’s reported figures.

Based on the most recent quarter.

The official record: Liquidia Corporation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Liquidia Corporation's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Liquidia Corporation's price / sales?
Liquidia Corporation (LQDA) reported price / sales of 11.5× in Q1 2026.
How has Liquidia Corporation's price / sales changed year-over-year?
Liquidia Corporation's price / sales decreased by 87.0% year-over-year, from 89× to 11.5×.
What is the long-term trend for Liquidia Corporation's price / sales?
Over 5 years (2020 to 2025), Liquidia Corporation's price / sales has grown at a -38.0% compound annual growth rate (CAGR), from 207.3× to 19×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.